Cansino OTC Stock Financials

CASBF
 Stock
  

USD 14.61  0.47  3.12%   

You can use fundamental analysis to find out if Cansino Biologics is mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We have analyzed twenty-nine available fundamental indicators for Cansino Biologics, which can be compared to its rivals. To ensure the equity is not overpriced, please confirm all Cansino Biologics financials, including its price to earning, net income, book value per share, as well as the relationship between the revenue and total debt . Given that Cansino Biologics has a shares owned by institutions of 40.70 %, we suggest you to validate Cansino Biologics prevailing market performance to make sure the company can sustain itself down the road. Use Cansino Biologics to protect your portfolios against small market fluctuations. Benchmarks are essential to demonstrate the utility of optimization algorithms. The stock experiences an unexpected downward movement. The market is reacting to new fundamentals. Check odds of Cansino Biologics to be traded at $14.03 in 90 days.
  
With this module, you can analyze Cansino financials for your investing period. You should be able to track the changes in Cansino Biologics individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.
Understanding current and past Cansino Biologics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Cansino Biologics' financial statements are interrelated, with each one affecting the others. For example, an increase in Cansino Biologics' assets may result in an increase in income on the income statement.
Chance Of Financial Distress
Over 58
Cansino Biologics has more than 58 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for Cansino Biologics otc stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info
The data published in Cansino Biologics' official financial statements usually reflect Cansino Biologics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Cansino Biologics. For example, before you start analyzing numbers published by Cansino accountants, it's critical to develop an understanding of what Cansino Biologics' liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Cansino Biologics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cansino Biologics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Cansino Biologics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Cansino Biologics. Please utilize our Beneish M Score to check the likelihood of Cansino Biologics' management to manipulate its earnings.

Cansino Biologics Company Summary

Cansino Biologics competes with CYTRX CORP. CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the Peoples Republic of China. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the Peoples Republic of China. Cansino Biologics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 1946 people.
InstrumentUSA OTC Stock View All
ExchangeOTC Exchange
Business Address401-420, Biomedical Park
SectorHealthcare
IndustryDrug Manufacturers—Specialty & Generic
BenchmarkDOW
Websitewww.cansinotech.com
Phone400 922 2099
CurrencyUSD - US Dollar
You should never invest in Cansino Biologics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Cansino OTC Stock, because this is throwing your money away. Analyzing the key information contained in Cansino Biologics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Cansino Biologics Key Financial Ratios

Generally speaking, Cansino Biologics' financial ratios allow both analysts and investors to convert raw data from Cansino Biologics' financial statements into concise, actionable information that can be used to evaluate the performance of Cansino Biologics over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Cansino Biologics reports annually and quarterly.

Cansino Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Cansino Biologics's current stock value. Our valuation model uses many indicators to compare Cansino Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cansino Biologics competition to find correlations between indicators driving Cansino Biologics's intrinsic value. More Info.
Cansino Biologics is the top company in current valuation category among related companies. It is number one stock in gross profit category among related companies . . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cansino Biologics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cansino Biologics' OTC Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cansino Biologics' earnings, one of the primary drivers of an investment's value.

Cansino Biologics Systematic Risk

Cansino Biologics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Cansino Biologics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Beta measures systematic risk based on how returns on Cansino Biologics correlated with the market. If Beta is less than 0 Cansino Biologics generally moves in the opposite direction as compared to the market. If Cansino Biologics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Cansino Biologics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Cansino Biologics is generally in the same direction as the market. If Beta > 1 Cansino Biologics moves generally in the same direction as, but more than the movement of the benchmark.
.

About Cansino Biologics Financials

What exactly are Cansino Biologics Financials? Typically, a company's financial statements are the reports that show the financial position of the company. Three primary documents fall into the category of financial statements. These documents include Cansino Biologics' income statement, its balance sheet, and the statement of cash flows. Potential Cansino Biologics investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Cansino Biologics investors may use each financial statement separately, they are all related. The changes in Cansino Biologics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Cansino Biologics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Cansino Biologics is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Cansino has grown by more than 25% over the last five years, then there is a good chance that it will continue growing at least by 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it.

Cansino Biologics November 26, 2022 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Cansino Biologics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Cansino Biologics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Cansino Biologics based on widely used predictive technical indicators. In general, we focus on analyzing Cansino OTC Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Cansino Biologics's daily price indicators and compare them against related drivers.
Downside Deviation7.22
Information Ratio0.1555
Maximum Drawdown42.12
Value At Risk(7.13)
Potential Upside18.99
Continue to Trending Equities. Note that the Cansino Biologics information on this page should be used as a complementary analysis to other Cansino Biologics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.

Complementary Tools for Cansino OTC Stock analysis

When running Cansino Biologics price analysis, check to measure Cansino Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cansino Biologics is operating at the current time. Most of Cansino Biologics' value examination focuses on studying past and present price action to predict the probability of Cansino Biologics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Cansino Biologics' price. Additionally, you may evaluate how the addition of Cansino Biologics to your portfolios can decrease your overall portfolio volatility.
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Please note, there is a significant difference between Cansino Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine Cansino Biologics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cansino Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.